INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MiNK Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.56+0.15 (+1.59%)
Close on Oct 19, 2026
- Market cap
- $48.02M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.44 (−31.71%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $48.02M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.36M
- EPS, diluted
- -$2.40
- Book value per share
- -$2.79
- Diluted shares
- 5M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$11.99M
Net income
-$11.36M
EPS, diluted
-$2.40
Free cash flow
–
Reported periodTrailing twelve months